全文获取类型
收费全文 | 1201378篇 |
免费 | 86793篇 |
国内免费 | 9486篇 |
专业分类
耳鼻咽喉 | 16046篇 |
儿科学 | 36256篇 |
妇产科学 | 30105篇 |
基础医学 | 172069篇 |
口腔科学 | 31986篇 |
临床医学 | 110396篇 |
内科学 | 220122篇 |
皮肤病学 | 25879篇 |
神经病学 | 87318篇 |
特种医学 | 47584篇 |
外国民族医学 | 266篇 |
外科学 | 175455篇 |
综合类 | 44755篇 |
现状与发展 | 30篇 |
一般理论 | 275篇 |
预防医学 | 83328篇 |
眼科学 | 27656篇 |
药学 | 101527篇 |
126篇 | |
中国医学 | 10416篇 |
肿瘤学 | 76062篇 |
出版年
2021年 | 13094篇 |
2020年 | 10125篇 |
2019年 | 12353篇 |
2018年 | 16079篇 |
2017年 | 13343篇 |
2016年 | 14266篇 |
2015年 | 17434篇 |
2014年 | 22878篇 |
2013年 | 29556篇 |
2012年 | 40877篇 |
2011年 | 43275篇 |
2010年 | 26682篇 |
2009年 | 24023篇 |
2008年 | 37379篇 |
2007年 | 39478篇 |
2006年 | 39425篇 |
2005年 | 37182篇 |
2004年 | 34479篇 |
2003年 | 33152篇 |
2002年 | 31406篇 |
2001年 | 63073篇 |
2000年 | 64015篇 |
1999年 | 53098篇 |
1998年 | 13398篇 |
1997年 | 12063篇 |
1996年 | 11493篇 |
1995年 | 11423篇 |
1994年 | 10350篇 |
1993年 | 9533篇 |
1992年 | 38609篇 |
1991年 | 37050篇 |
1990年 | 36431篇 |
1989年 | 34911篇 |
1988年 | 31424篇 |
1987年 | 30461篇 |
1986年 | 28660篇 |
1985年 | 26816篇 |
1984年 | 19486篇 |
1983年 | 16339篇 |
1982年 | 9027篇 |
1979年 | 17165篇 |
1978年 | 11537篇 |
1977年 | 10362篇 |
1975年 | 10153篇 |
1974年 | 11763篇 |
1973年 | 11367篇 |
1972年 | 10834篇 |
1971年 | 10194篇 |
1970年 | 9336篇 |
1969年 | 9013篇 |
排序方式: 共有10000条查询结果,搜索用时 375 毫秒
91.
92.
93.
目的 评估检测大肠肿瘤患者粪便中SEPT-9和微RNA(miRNA)-34b/c基因甲基化对大肠肿瘤筛查的临床性能。方法 采用病例对照研究方法,使用甲基化敏感性高分辨率熔解曲线法检测大肠肿瘤患者(大肠癌组35例、大肠腺瘤组47例)和正常对照人群(正常对照组52名)粪便中SEPT-9和miRNA-34b/c基因是否存在甲基化,来评估其筛查大肠肿瘤的性能。结果 大肠癌组SEPT-9和miRNA-34b/c基因的甲基化阳性率分别为68.6%、71.4%,大肠腺瘤组分别为57.4%、63.8%,正常对照组分别为9.6%、11.5%。3组的SEPT-9、miRNA-34b/c基因甲基化阳性率比较差异均有统计学意义(2SEPT-9 = 37.185,2miRNA-34b/c = 40.040,P均< 0.001),利用Bonferroni法进行两两比较,大肠癌组和大肠腺瘤组的甲基化阳性率比较差异无统计学意义,两者与正常对照组比较差异均有统计学意义(P均< 0.001)。3组联合检测SEPT-9和miRNA-34b/c基因的甲基化阳性率为88.6%、76.6%、13.5%,大肠癌组和大肠腺瘤组联合检测的甲基化阳性率均高于SEPT-9单基因检测和miRNA-34b/c单基因检测(P均< 0.05)。结论 检测粪便中SEPT-9和miRNA-34b/c基因甲基化具有效好的大肠肿瘤筛查性能,或许可作为大规模人群筛查大肠肿瘤新的生物标志物组合;多基因甲基化联合检测筛查的性能优于单基因。 相似文献
94.
95.
目的采用髓内钉辅助延长技术进行儿童股骨大段延长,评估其可行性,并对比同期矫正和分期手术的技术要点,明确此技术在儿童患儿中的应用价值。方法自2014年7月7日至2018年1月16日共规划完成逆行髓内钉辅助延长手术10例,其中男9例,女1例;年龄(13.10±2.18)岁。所有患儿延长截骨点均位于股骨远端干骺端,初诊至末次随访记录内容包括:性别、出生日期、不等长病因及治疗史、术时年龄、延长长度、带架时间、延长段愈合时间、屈膝角度、并发症等。比较同期延长和分期矫正的愈合时间,采用SPSS 22.0软件进行统计分析,提出合理的治疗策略。结果10例患儿患肢平均延长(7.07±1.01)cm,中位带架时间为8.5(4,16)个月,中位随访时间为39(34,54)个月。所有病例均获得了良好的临床和影像学愈合,并全部恢复正常行走功能,无延长后骨折发生。同期矫正与分期手术间在愈合速度为[(1.70±1.10)月/cm vs.(1.16±0.54)月/cm],膝关节功能(136.67°±20.82°vs.125.71°±26.37°)和并发症率方面的差异均无统计学意义。结论外固定架辅助逆行髓内钉技术进行股骨延长治疗儿童股骨短缩畸形是可行的,是股骨延长的有效手术方式之一;较轻的角度畸形和延长手术可同期进行;干骺端截骨延长成骨质量更佳,可有效减少带架时间;内生软骨瘤患儿的病变区延长是安全的。 相似文献
96.
Erik de Bakker Mirthe A. M. van der Putten Martijn W. Heymans Sander W. Spiekstra Taco Waaijman Liselotte Butzelaar Vera L. Negenborn Vivian K. Beekman Erman O. Akpinar Thomas Rustemeyer Frank B. Niessen Susan Gibbs 《Experimental dermatology》2021,30(1):169-178
Unpredictable hypertrophic scarring (HS) occurs after approximately 35% of all surgical procedures and causes significant physical and psychological complaints. Parallel to the need to understanding the mechanisms underlying HS formation, a prognostic tool is needed. The objective was to determine whether (systemic) immunological differences exist between patients who develop HS and those who develop normotrophic scars (NS) and to assess whether those differences can be used to identify patients prone to developing HS. A prospective cohort study with NS and HS groups in which (a) cytokine release by peripheral blood mononuclear cells (PBMC) and (b) the irritation threshold (IT) after an irritant (sodium lauryl sulphate) patch test was evaluated. Univariate regression analysis of PBMC cytokine secretion showed that low MCP‐1, IL‐8, IL‐18 and IL‐23 levels have a strong correlation with HS (P < .010‐0.004; AUC = 0.790‐0.883). Notably, combinations of two or three cytokines (TNF‐a, MCP‐1 and IL‐23; AUC: 0.942, Nagelkerke R2: 0.727) showed an improved AUC indicating a better correlation with HS than single cytokine analysis. These combination models produce good prognostic results over a broad probability range (sensitivity: 93.8%, specificity 86.7%, accuracy 90,25% between probability 0.3 and 0.7). Furthermore, the HS group had a lower IT than the NS group and an accuracy of 68%. In conclusion, very fundamental immunological differences exist between individuals who develop HS and those who do not, whereas the cytokine assay forms the basis of a predictive prognostic test for HS formation, the less invasive, easily performed irritant skin patch test is more accessible for daily practice. 相似文献
97.
98.
A. Thomas S. Manchella K. Koo A. Tiong A. Nastri D. Wiesenfeld 《International journal of oral and maxillofacial surgery》2021,50(5):585-590
The contemporary literature is discordant regarding the role of delayed diagnosis in the prognosis of patients with oral cancer. This study examined data on a previously reported cohort of 101 patients with oral squamous cell carcinoma diagnosed at a single institution between 2008 and 2010. The time interval between symptom onset and initial histological diagnosis (diagnostic delay) was recorded for each patient, as were demographic data and cancer features such as T stage, nodal status, and smoking status. The mean follow-up period was 4 years 10 months. The mean diagnostic delay was 4 months, mean overall survival was 5 years 6 months, and mean disease-specific survival was 4 years 9 months. No significant correlation was found between diagnostic delay and overall survival, disease-specific survival, or recurrence rates. Patients with node-positive disease were more likely to be diagnosed earlier, whereas women and non-smokers were more likely to have a delayed diagnosis. Inherent tumour biology is likely an important prognostic factor separate to diagnostic delay. Public education efforts should focus on symptom recognition and encourage early presentation for investigation of oral lesions, particularly for females and non-smokers, so that more aggressive tumours can be treated sooner to give the best chance at survival. 相似文献
99.
100.
Amandeep R. Mahal Laura D. Cramer Elyn H. Wang Shiyi Wang Amy J. Davidoff Cary P. Gross James B. Yu 《Journal of Geriatric Oncology》2021,12(1):102-105
ObjectivesAlthough survival after a cancer diagnosis has improved considerably over the past 20 years, little is known about trends in health-related quality-of-life (HRQOL) for older prostate, breast, and lung cancer survivors.MethodsUsing a population-based registry with longitudinal patient reported outcomes (the National Cancer Institute Surveillance, Epidemiology and End Results database linked to Medicare Health Outcomes Survey), we analyzed Medicare Advantage patients diagnosed with cancer during 1998–2011, who completed surveys regarding HRQOL through 2013. ‘Early Era’ patients were treated during 1998–2003; ‘Late Era’ patients were treated during 2006–2011. After propensity score matching, post-diagnosis changes in health utility (HU), Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated and compared between the two eras.ResultWe identified 208 older patients with prostate, 276 with breast and 76 with lung cancer who were treated in the ‘Early Era’ and matched to equal numbers in the ‘Late Era’. Mean age of patients in early and late era was 72 and 73 years, respectively. The mean post-diagnosis decline in health utility for patients treated in the ‘Late Era’ was not significantly different from the ‘Early Era’ for any cancer (Prostate [early vs. late]: ?0.06 vs. -0.03, p = .09; Breast: ?0.03 vs. ?0.04, p = .65; Lung: ?0.07 vs. ?0.07, p = .95); nor for Physical Component Summary or Mental Component Summary scores.ConclusionOlder patients treated for prostate, breast or lung cancer in the later era reported similar outcomes of changes in HRQOL compared to earlier era patients. 相似文献